Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

J William L Brown; Nick G Cunniffe; Ferran Prados; Baris Kanber; Joanne L Jones; Edward Needham; Zoya Georgieva; David Rog; Owen R Pearson; James Overell; David Macmanus; Rebecca S Samson; Jonathan Stutters; Charles Ffrench-constant; Claudia A M Gandini Wheeler-kingshott; Carla Moran; Paul D Flynn; Andrew W Michell; Robin J M Franklin; Siddharthan Chandran; Daniel R Altmann; Declan T Chard; Peter Connick; Alasdair J Coles

doi:10.1016/S1474-4422(21)00179-4

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

J William L Brown, Nick G Cunniffe, Ferran Prados, Baris Kanber, Joanne L Jones, Edward Needham, Zoya Georgieva, David Rog, Owen R Pearson, James Overell, David Macmanus, Rebecca S Samson, Jonathan Stutters, Charles Ffrench-constant, Claudia A M Gandini Wheeler-kingshott, Carla Moran, Paul D Flynn, Andrew W Michell, Robin J M Franklin, Siddharthan ChandranDaniel R Altmann, Declan T Chard, Peter Connick, Alasdair J Coles

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	709-720
Journal	The Lancet Neurology
Volume	20
Issue number	9
DOIs	https://doi.org/10.1016/S1474-4422(21)00179-4
Publication status	Published - 1 Sept 2021

Access to Document

10.1016/S1474-4422(21)00179-4

CCMR One main text 16 May CLEANED
This is the author's peer-reviewed manuscript as accepted for publication.
Accepted author manuscript, 95.6 KBLicence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S1474442221001794

Cite this

Brown, J. W. L., Cunniffe, N. G., Prados, F., Kanber, B., Jones, J. L., Needham, E., Georgieva, Z., Rog, D., Pearson, O. R., Overell, J., Macmanus, D., Samson, R. S., Stutters, J., Ffrench-constant, C., Gandini Wheeler-kingshott, C. A. M., Moran, C., Flynn, P. D., Michell, A. W., Franklin, R. J. M., ... Coles, A. J. (2021). Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. The Lancet Neurology, 20(9), 709-720. https://doi.org/10.1016/S1474-4422(21)00179-4

@article{61820e467a36403a8fc2c1e241e4facc,

title = "Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study",

author = "Brown, {J William L} and Cunniffe, {Nick G} and Ferran Prados and Baris Kanber and Jones, {Joanne L} and Edward Needham and Zoya Georgieva and David Rog and Pearson, {Owen R} and James Overell and David Macmanus and Samson, {Rebecca S} and Jonathan Stutters and Charles Ffrench-constant and {Gandini Wheeler-kingshott}, {Claudia A M} and Carla Moran and Flynn, {Paul D} and Michell, {Andrew W} and Franklin, {Robin J M} and Siddharthan Chandran and Altmann, {Daniel R} and Chard, {Declan T} and Peter Connick and Coles, {Alasdair J}",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/S1474-4422(21)00179-4",

language = "English",

volume = "20",

pages = "709--720",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Science",

number = "9",

}

Brown, JWL, Cunniffe, NG, Prados, F, Kanber, B, Jones, JL, Needham, E, Georgieva, Z, Rog, D, Pearson, OR, Overell, J, Macmanus, D, Samson, RS, Stutters, J, Ffrench-constant, C, Gandini Wheeler-kingshott, CAM, Moran, C, Flynn, PD, Michell, AW, Franklin, RJM, Chandran, S, Altmann, DR, Chard, DT, Connick, P & Coles, AJ 2021, 'Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study', The Lancet Neurology, vol. 20, no. 9, pp. 709-720. https://doi.org/10.1016/S1474-4422(21)00179-4

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. / Brown, J William L; Cunniffe, Nick G; Prados, Ferran et al.
In: The Lancet Neurology, Vol. 20, No. 9, 01.09.2021, p. 709-720.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

AU - Brown, J William L

AU - Cunniffe, Nick G

AU - Prados, Ferran

AU - Kanber, Baris

AU - Jones, Joanne L

AU - Needham, Edward

AU - Georgieva, Zoya

AU - Rog, David

AU - Pearson, Owen R

AU - Overell, James

AU - Macmanus, David

AU - Samson, Rebecca S

AU - Stutters, Jonathan

AU - Ffrench-constant, Charles

AU - Gandini Wheeler-kingshott, Claudia A M

AU - Moran, Carla

AU - Flynn, Paul D

AU - Michell, Andrew W

AU - Franklin, Robin J M

AU - Chandran, Siddharthan

AU - Altmann, Daniel R

AU - Chard, Declan T

AU - Connick, Peter

AU - Coles, Alasdair J

PY - 2021/9/1

Y1 - 2021/9/1

U2 - 10.1016/S1474-4422(21)00179-4

DO - 10.1016/S1474-4422(21)00179-4

M3 - Article

SN - 1474-4422

VL - 20

SP - 709

EP - 720

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 9

ER -

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

Access to Document

Other files and links

Cite this